International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

被引：121

作者：

Lokhorst, Henk

Einsele, Hermann

Vesole, David

Bruno, Benedetto

Miguel, Jesus San

Perez-Simon, Jose A.

Kroger, Nicolaus

Moreau, Philippe

Gahrton, Gosta

Gasparetto, Cristina

Giralt, Sergio

Bensinger, William

机构：

[1] Univ Utrecht Hosp, Utrecht, Netherlands

[2] Univ Hosp Wuerzburg, Wurzburg, Germany

[3] Univ Hosp Hamburg Eppendorf, Hamburg, Germany

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Turin, Giovanni Battista Hosp, Turin, Italy

[6] Univ Hosp Salamanca, Salamanca, Spain

[7] Ctr Hosp Univ Hotel Dieu, Nantes, France

[8] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden

[9] Duke Univ Hosp, Durham, NC USA

[10] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期

关键词：

VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; IN-SITU HYBRIDIZATION; TANDEM AUTOLOGOUS TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; COOPERATIVE-ONCOLOGY-GROUP; NEWLY-DIAGNOSED MYELOMA; HIGH-DOSE CHEMOTHERAPY; RELAPSE-FREE SURVIVAL;

D O I：

10.1200/JCO.2010.29.7929

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology

引用

页码：4521 / 4530

页数：10

共 107 条

[1] Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model [J].

Alici, Evren ;

Konstantinidis, Kyriakos V. ;

Sutlu, Tolga ;

Aints, Alar ;

Gahrton, Gosta ;

Ljunggren, Hans-Gustaf ;

Dilber, M. Sirac .

EXPERIMENTAL HEMATOLOGY, 2007, 35 (12) :1839-1846

[2] Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation [J].

Atanackovic, Djordje ;

Arfsten, Julia ;

Cao, Yanran ;

Gnjatic, Sacha ;

Schnieders, Frank ;

Bartels, Katrin ;

Schilling, Georgia ;

Faltz, Christiane ;

Wolschke, Christine ;

Dierlamm, Judith ;

Ritter, Gerd ;

Eiermann, Thomas ;

Hossfeld, Dieter Kurt ;

Zander, Axel R. ;

Jungbluth, Achim A. ;

Old, Lloyd J. ;

Bokemeyer, Carsten ;

Kroeger, Nicolaus .

BLOOD, 2007, 109 (03) :1103-1112

[3] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[4] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].

Avet-Loiseau, H ;

Facon, T ;

Grosbois, B ;

Magrangeas, F ;

Rapp, MJ ;

Harousseau, JL ;

Minvielle, S ;

Bataille, R .

BLOOD, 2002, 99 (06) :2185-2191

[5] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[6] Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma [J].

Barbui, AM ;

Galli, M ;

Dotti, G ;

Belli, N ;

Borleri, G ;

Gritti, G ;

Bellavita, P ;

Viero, P ;

Comotti, B ;

Barbui, T ;

Rambaldi, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) :202-210

[7] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[8] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321 [J].

Barlogie, B ;

Kyle, RA ;

Anderson, KC ;

Greipp, PR ;

Lazarus, HM ;

Hurd, DD ;

McCoy, J ;

Dakhil, SR ;

Lanier, KS ;

Chapman, RA ;

Cromer, JN ;

Salmon, SE ;

Durie, B ;

Crowley, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :929-936

[9] Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].

Barlogie, Bart ;

Anaissie, Elias ;

van Rhee, Frits ;

Haessler, Jeffrey ;

Hollmig, Klaus ;

Pineda-Roman, Mauricio ;

Cottler-Fox, Michele ;

Mohiuddin, Abid ;

Alsayed, Yazan ;

Tricot, Guido ;

Bolejack, Vanessa ;

Zangari, Maurizio ;

Epstein, Joshua ;

Petty, Nathan ;

Steward, Douglas ;

Jenkins, Bonnie ;

Gurley, Jennifer ;

Sullivan, Ellen ;

Crowley, John ;

Shaughnessy, John D. Jr .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185

[10] Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation [J].

Baron, Frederic ;

Storb, Rainer ;

Storer, Barry E. ;

Maris, Michael B. ;

Niederwieser, Dietger ;

Shizuru, Judith A. ;

Chauncey, Thomas R. ;

Bruno, Benedetto ;

Forman, Stephen J. ;

McSweeney, Peter A. ;

Maziarz, Richard T. ;

Pulsipher, Michael A. ;

Agura, Edward D. ;

Wade, James ;

Sorror, Mohamed ;

Maloney, David G. ;

Sandmaier, Brenda M. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4150-4157

← 1 2 3 4 5 6 7 8 9 10 →